

# Bavisant (dihydrochloride hydrate)

Catalog No: tcsc1459



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1103522-80-0

**Formula:**

$C_{19}H_{31}Cl_2N_3O_3$

**Pathway:**

Immunology/Inflammation;GPCR/G Protein

**Target:**

Histamine Receptor;Histamine Receptor

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O : ≥ 50 mg/mL (118.94 mM); DMSO : ≥ 1 mg/mL (2.38 mM)

**Alternative Names:**

JNJ31001074AAC

**Observed Molecular Weight:**

420.37

## Product Description

Bavisant Hcl hydrate(JNJ-31001074) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.


IC50 Value:

Target: H3 receptor

in vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1].

in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo ( $p=0.161$ ), and hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed [2].

Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!